시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 차세대 시퀀싱(NGS) 기반 분자진단 시장 보고서(2025년)
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Global Market Report 2025
상품코드 : 1855935
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,650,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,612,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,575,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 차세대 시퀀싱(NGS) 기반 분자진단 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 21억 달러에서 2025년에는 22억 6,000만 달러에 달하고, CAGR 7.8%로 확대될 것으로 보입니다. 기간 중 성장은 맞춤형 의료에 대한 수요 증가, 임상 현장에서 차세대 시퀀싱의 광범위한 채용, 임상의와 환자 의식 증가, 비용 효율적인 NGS 플랫폼의 가용성 확대, 비침습적 출생 전 검사의 용도 확대와 관련이 있습니다.

차세대 시퀀싱(NGS) 기반 분자진단 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.4%로 30억 1,000만 달러로 성장합니다. 기간 동안 예측되는 성장은 분산 진단 솔루션에 대한 수요 증가, NGS 데이터 분석에서 인공지능 활용 증가, 항생제 내성 부담 증가, NGS 기반 검사에 대한 규제 당국의 지원 강화, 약리 유전체학에서 NGS 활용의 확대로 이어집니다. 예측 기간 동안 주요 동향에는 시퀀싱 정확도 향상, 시료 준비 기술 주도 자동화, 의약품 개발 파이프라인과의 통합, 공중 보건 감시에 NGS 통합, 질병 특이 NGS 패널 개발 등이 포함됩니다.

감염증의 이환율 증가는 향후 수년간 차세대 시퀀싱(NGS) 기반 분자진단 시장의 성장을 가속할 것으로 예측됩니다. 감염은 박테리아, 바이러스, 곰팡이, 기생충 등의 미생물이 체내에 침입하여 증식하고 정상적인 기능을 파괴함으로써 발생하는 질병입니다. 세계적인 여행과 이주 증가는 지역과 국경을 넘어 병원체의 확산을 조장하고 감염증 환자 증가에 박차를 가하고 있습니다. NGS 기반 분자진단은 병원체의 종합적이고 정밀한 분석을 제공함으로써 이러한 질병의 검출을 지원하고, 여러 미생물의 동시 동정을 가능하게 함으로써 진단 시간을 단축하고, 치료 정밀도와 환자 케어를 향상시킵니다. 예를 들어, 2024년 2월 영국 건강 안보국은 영국에서 결핵 환자가 10.7% 증가했으며 2022년 4,380명에서 2023년 4,850명으로 증가했다고 보고했습니다. 그 결과 감염증의 이환율이 증가하면 NGS 기반 분자진단에 대한 수요가 증가하고 있습니다.

NGS 기반 분자진단 시장의 주요 기업은 유전자 검사의 정확성, 접근성 및 효율성을 향상시키기 위해 표적 NGS 패널과 같은 고급 제품을 개발하고 있습니다. 이 NGS 패널은 특정 유전자와 유전체 영역을 동시에 분석하여 유전성 및 체세포 돌연변이를 신속하고 정확하게 검출합니다. 예를 들어, 2022년 5월, 인도의 의료기기 제조업체인 Genes2Me Pvt. Ltd.는 종양학, 맞춤형 의료, 유전성 질환 진단을 위한 종합적인 일련의 NGS 패널을 발표했습니다. 이 패널은 임상적으로 중요한 유전자를 고감도로 커버하고, 단일 염기 돌연변이, 삽입 및 결실, 복제 수 변이, 마이크로 위성 불안정성, 융합, 발암성 바이러스, 종양 돌연변이 부하를 포함한 다양한 유전체 변화를 검출합니다. 이 회사의 PAN 암 패널은 약 525개의 유전자를 타겟으로 하며, 오직 50ng의 핵산을 필요로 하며, 주요 NGS 플랫폼과 호환되는 합리화된 워크플로우를 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Next-generation sequencing (NGS)-based molecular diagnostics is a technology-driven approach that uses high-throughput sequencing to analyze genetic material with precision and speed. It enables detection of genetic variations, mutations, and disease markers at the molecular level, providing detailed insights into the genetic basis of health and disease. This approach supports precise, data-driven diagnostics by combining sequencing technologies with advanced bioinformatics.

The primary types of NGS-based molecular diagnostics include instruments, reagents and consumables, software and services, panels and assays, and sample preparation kits. NGS instruments are the hardware platforms, such as sequencers and automation workstations, used to perform high-throughput DNA/RNA sequencing. Applications include microbiology, infectious diseases, oncology, genetic testing, and other areas. End users include research centers, academic institutions, hospitals, clinical laboratories, and other organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The next-generation sequencing (NGS) based molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides next-generation sequencing (NGS) based molecular diagnostics market statistics, including next-generation sequencing (NGS) based molecular diagnostics industry global market size, regional shares, competitors with a next-generation sequencing (NGS) based molecular diagnostics market share, detailed next-generation sequencing (NGS) based molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (NGS) based molecular diagnostics industry. The next-generation sequencing (NGS)-based molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation sequencing (NGS)-based molecular diagnostics market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period is linked to increasing demand for personalized medicine, wider adoption of next-generation sequencing in clinical settings, growing awareness among clinicians and patients, greater availability of cost-effective NGS platforms, and expanding applications in non-invasive prenatal testing.

The next-generation sequencing (NGS)-based molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth projected for the forecast period is driven by rising demand for decentralized diagnostic solutions, increasing use of artificial intelligence in NGS data interpretation, growing burden of antibiotic resistance, enhanced regulatory support for NGS-based tests, and greater utilization of NGS in pharmacogenomics. Primary trends during the forecast period include advancements in sequencing accuracy, technology-driven automation in sample preparation, integration with pharmaceutical development pipelines, incorporation of NGS into public health surveillance, and development of disease-specific NGS panels.

The rising incidence of infectious diseases is expected to drive growth in the next-generation sequencing (NGS)-based molecular diagnostics market in the coming years. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade and multiply within the body, disrupting normal functions. Increasing global travel and migration contribute to the spread of pathogens across regions and borders, fueling the rise in infectious disease cases. NGS-based molecular diagnostics aids in detecting these diseases by offering comprehensive and precise analysis of pathogens, enabling simultaneous identification of multiple microorganisms, which shortens diagnostic time and improves treatment accuracy and patient care. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7%, rising from 4,380 in 2022 to 4,850 in 2023. Consequently, the growing incidence of infectious diseases is propelling the demand for NGS-based molecular diagnostics.

Key players in the NGS-based molecular diagnostics market are developing advanced products such as targeted NGS panels to improve the accuracy, accessibility, and efficiency of genetic testing. These NGS panels analyze specific genes or genomic regions simultaneously to detect hereditary or somatic mutations quickly and accurately. For instance, in May 2022, Genes2Me Pvt. Ltd., an Indian medical equipment manufacturer, introduced a comprehensive series of NGS panels aimed at oncology, personalized medicine, and hereditary disease diagnostics. These panels cover clinically significant genes with high sensitivity and detect various genomic alterations, including single-nucleotide variants, insertions/deletions, copy number variations, microsatellite instability, fusions, oncogenic viruses, and tumor mutation burden. Their PAN cancer panel targets about 525 genes, requiring only 50 ng of nucleic acid, and supports streamlined workflows compatible with major NGS platforms.

In January 2023, QIAGEN NV, a molecular diagnostics and life sciences company based in Germany, acquired Verogen Inc. for an undisclosed sum. This acquisition aims to enhance QIAGEN's leadership in human identification and forensic genomics by integrating Verogen's specialized NGS technologies into its broader molecular diagnostics portfolio. This expansion strengthens QIAGEN's presence in public sector forensics and private sector applications such as genetic genealogy. Verogen Inc. is a US-based company specializing in NGS solutions for forensic genomics.

Major players in the next-generation sequencing (NGS)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., and TATAA Biocenter AB.

North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation sequencing (NGS)-based molecular diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next-generation sequencing (NGS)-based molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation sequencing (NGS)-based molecular diagnostics market includes revenues earned by entities by providing services, such as clinical genomic testing, cancer genomic profiling, infectious disease detection, liquid biopsy testing, and pharmacogenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS)-based molecular diagnostics market also includes sales of tumor mutation panels, carrier screening kits, drug response panels, companion diagnostic kits, and whole-genome metagenomics kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next-generation sequencing (ngs)-based molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for next-generation sequencing (ngs)-based molecular diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation sequencing (ngs)-based molecular diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Characteristics

3. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Trends And Strategies

4. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Growth Analysis And Strategic Analysis Framework

6. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Segmentation

7. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

9. China Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

10. India Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

11. Japan Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

12. Australia Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

13. Indonesia Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

14. South Korea Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

15. Western Europe Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

16. UK Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

17. Germany Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

18. France Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

19. Italy Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

20. Spain Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

21. Eastern Europe Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

22. Russia Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

23. North America Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

24. USA Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

25. Canada Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

26. South America Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

27. Brazil Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

28. Middle East Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

29. Africa Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

30. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Competitive Landscape And Company Profiles

31. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Other Major And Innovative Companies

32. Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

34. Recent Developments In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

35. Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기